DRMA vs RCUS

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 03, 2026

DRMA

60.8
AI Score
VS
RCUS Wins

RCUS

65.7
AI Score

Investment Advisor Scores

DRMA

61score
Recommendation
BUY

RCUS

66score
Recommendation
BUY

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric DRMA RCUS Winner
Net Income -4.81M -353.00M DRMA
Operating Income -4.94M -386.00M DRMA
ROE -138.0% -55.9% RCUS
ROA -90.5% -31.0% RCUS
Total Assets 5.32M 1.14B RCUS
Cash 4.41M 222.00M RCUS
Current Ratio 3.40 4.36 RCUS
Free Cash Flow -5.01M -484.00M DRMA

Relative Price Performance (Last 90 Days)

DRMA 1M: -13.7% · 3M: -17.5% RCUS 1M: -18.1% · 3M: -18.5%

Current Technical Phase

DRMA

Markdown
Sell / avoid

Price below a falling SMA50 (slope -4.8%), weak momentum, RSI 40

RSI (14): 39.6 · Price: $1.11

RCUS

Markdown
Sell / avoid

Price below a falling SMA50 (slope -4.8%), weak momentum, RSI 37

RSI (14): 36.9 · Price: $24.44

Fundamentals Snapshot

Metric DRMA RCUS
Market Cap — —
Forward P/E -0.8 -7.5
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.0% -0.7%
Gross Margin — -3.2%
Operating Margin 0.0% -2.3%
EPS -4.24 -3.85
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, RCUS is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.